Particle.news

Charité Delivers CRISPR Gene‑Editing Therapy in Routine Care, Ending Teen’s Transfusion Dependence

The hospital says the May infusion restarted normal haemoglobin production but the treatment carries serious short‑term toxicities, likely infertility, and long‑term safety is still unknown.

Overview

  • Charité treated a 19‑year‑old beta‑thalassaemia patient with the EU‑approved CRISPR‑based therapy Exagamglogene Autotemcel after an individual case approval, with the infusion of more than 900 million edited stem cells performed on May 28, 2026.
  • Doctors harvested the patient’s blood stem cells, sent them to manufacturer labs in the Netherlands for CRISPR editing to reactivate fetal (gamma) globin, gave high‑dose chemotherapy to make space in the bone marrow, and then reinfused the modified cells.
  • About 40 days after the infusion the patient began producing the missing haemoglobin, his total haemoglobin reached the normal range, and he no longer needs regular blood transfusions.
  • The therapy requires toxic preconditioning that can cause painful mucositis and liver injury and very likely causes infertility, and regulators have made approval conditional with a required 15‑year follow‑up because long‑term safety and durability remain unproven.
  • Payer and capacity limits will restrict access: German insurers will cover treatment only after special applications, reimbursement terms with the manufacturer are confidential, and the complex logistics and specialist centers mean only a limited number of patients can be treated each year.